Keurig Dr Pepper Inc. Common Stock vs Novavax Inc — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $31.76 (market cap $42.54B), while Novavax Inc trades at $12.7 (market cap $1.82B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 23.4× Novavax Inc's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.94% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 1 Days and Novavax Inc for 59 Days on average.
| KDP | NVAX | |
|---|---|---|
Market Cap | $42.54B | $1.82B |
Volume | 14,530,234 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $12.56 |
52-Week Low | $25.31 | $6.22 |
Typical Hold Time | 1 Days | 59 Days |
Enterprise Value | $71.00B | $1.39B |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →